UBX Unity Biotechnology: Multiplikator Forward P/S
The absence of debt and robust patent protection for Unity Biotechnology (UBX) have acted as growth catalysts, as confirmed by the precise GURU.Markets chart, where the forward P/S history shows 184.40 as the latest metric reading. This has solidified the success of senolytics in treating joints and eyes, confirming the company's status as a recognized leader in the field of combating cellular senescence.
UBX (Unity Biotechnology, Inc): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Unity Biotechnology|UBX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Unity Biotechnology|UBX - Utang perusahaan|Rasio utang marang kapitalisasi buku Unity Biotechnology, Inc|UBX - Utang jangka dawa|Utang jangka cendhak perusahaan Unity Biotechnology|Indikator likuiditas cepet unitybiotechnology.com
- rincian asil keuangan lan kelipatan valuasi:
UBX - Penghasilan resik perusahaan|Bathi mangsa ngarep Unity Biotechnology|UBX - Pangali P/E|Pangali Forward P/E Unity Bio|UBX - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Unity Biotechnology, Inc|UBX - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Unity Biotechnology|UBX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan unitybiotechnology.com|UBX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Unity Biotechnology
- statistik dodolan lan pendapatan perusahaan:
Ringkesan analitik perusahaan:UBX (Unity Biotechnology, Inc.)
To identify fundamental sector leaders, analysts utilize forward business value relative to expected sales, which allows them to capture shifts in institutional sentiment and avoid asset impairment. This calculation measures the issuer's long-term attractiveness, as the forward price-to-sales valuation chart reflects the gap between the potential of an aging population and the current lack of commercial demand due to the clinical development stage of Unity Biotechnology (UBX).
Analisis pesaing
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Qiagen NV (QGEN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Ionis Pharma - Multiplikator Forward P/S|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA: Multiplikator Forward P/S|crisprtx.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan GeneDx|Kapitalisasi marang prakiraan pendapatan RARE (Ultragenyx Pharmaceutical Inc.)|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|SRPT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Twist Bioscience TWST|10xgenomics.com - Rasio rega marang prakiraan pendapatan|NTLA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stoke Therapeutics Inc|BLFS: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Wave Pharma WVE|Multiplikator forward rega marang pendapatan MAZE|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep sionnatx.com SION|Multiplikator forward rega marang pendapatan PRME (Prime Medicine)|Multiplikator Forward P/S Taysha Gene Therapies Inc (TSHA)|Multiplikator Forward P/S QURE (uniQure Corp)|MeiraGTx Corp - Rasio rega marang prakiraan pendapatan|RGNX: Multiplikator forward rega marang pendapatan|SLDB (solidbio.com) - Kapitalisasi marang prakiraan pendapatan|OCGN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PACB|Rasio rega marang prakiraan pendapatan Benitec|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Multiplikator Forward P/S RCKT|Multiplikator Forward P/S 4dmoleculartherapeutics.com (FDMT)|Lexeo Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Korro Bio Inc. KRRO|EDIT - Rasio rega marang prakiraan pendapatan|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|PRQR: Multiplikator Forward P/S|CDXS - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan SGMO|NAUT (Nautilus Biotechnology Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan MGX (Metagenomi, Inc)|DTIL - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Generation Bio - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan BOLD|Exicure Corp - Multiplikator Forward P/S|IMNN: Rasio rega marang prakiraan pendapatan|PHIO: Multiplikator Forward P/S|MBIO - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan TransCode Therapeutics Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Bionano BNGO|Multiplikator forward rega marang pendapatan APDN (Applied DNA Sciences, Inc.)|Rasio rega marang pendapatan sing dikarepake BLUE|Multiplikator Forward P/S IPA (ImmunoPrecise Antibodies Ltd.)|Omega Therapeutics Corp (OMGA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Singular Genomics Systems - Multiplikator Forward P/S|regulusrx.com (RGLS) - Multiplikator forward rega marang pendapatan|SYRS: Multiplikator Forward P/S|Telesis Bio Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan TRACON
